Shots:
- The CHMP has recommended Minjuvi (tafasitamab) + rituximab & lenalidomide for the treatment of adult pts with r/r FL (Grade 1-3a) who received ≥1L of systemic therapy
- Opinion was based on the P-III (inMIND) trial (N=654) assessing Minjuvi combination vs PBO + rituximab & lenalidomide in r/r FL (n=548) & r/r nodal, splenic or extranodal MZL pts (≥18yrs.)
- Trial met its 1EP of improved investigator-based PFS (mPFS: 22.4 vs 13.9mos.), while IRC-assessed PFS was consistent with results (mPFS was not reached vs 16mos.). Data was shared at ASH’24, EHA’25, & ICML’25
Ref: Incyte | Image: Incyte | Press Release
Related News:- Incyte Reports the Health Canada’s Approval of Opzelura (Ruxolitinib) for Atopic Dermatitis (AD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
